Welcome to our dedicated page for Aprea Therapeutics SEC filings (Ticker: APRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aprea Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage oncology company developing targeted therapies for biomarker-defined cancers. Its Form 8-K disclosures cover material events such as clinical updates for APR-1051, operating and financial results, corporate presentation updates, private-placement financing, capital-structure information, and Nasdaq listing-compliance notices.
Proxy materials for Aprea address annual meeting procedures and shareholder voting matters. The filing record also identifies the company’s common stock under the symbol APRE and provides formal disclosures tied to governance, financing activity, public-company reporting obligations, and the development status of its precision medicine oncology programs.
Aprea Therapeutics, Inc. files a prospectus supplement registering 5,503,556 shares of Common Stock for resale by selling stockholders. The supplement updates the Prospectus dated December 29, 2025 and reflects assignments of Common Warrants to Squadron Master Fund LP. The resale includes (i) 26,459 shares issued in a private placement, (ii) 2,596,564 shares underlying pre-funded warrants, (iii) 2,623,023 shares underlying common stock purchase warrants, and (iv) 257,510 shares underlying warrants issued as placement compensation. The filing states there were 12,382,776 shares outstanding as of May 13, 2026. The supplement shows, including Squadron Master Fund LP: 536,480 shares listed as being offered, with post-offering beneficial ownership reported as 1,433,878 shares (9.99%).
Aprea Therapeutics, Inc. reported a Q1 2026 net loss of $3.3 million, slightly improved from $3.9 million a year earlier, as lower research and development spending offset the end of grant revenue. Cash and cash equivalents reached $46.5 million, and management believes this will fund operations into the first quarter of 2028.
Research and development expenses fell to $1.6 million, mainly from reduced ATRN-119 monotherapy activity, while general and administrative costs were stable at about $1.8 million. Operating cash outflow was $2.8 million in the quarter.
The company strengthened its balance sheet with approximately $34.6 million in net proceeds from January and March 2026 private placements involving common stock and pre-funded warrants. Aprea continues to advance its synthetic lethality oncology pipeline, including WEE1 inhibitor APR-1051 and ATR inhibitor ATRN-119, supported by an expanded base of warrants and equity capital.
Aprea Therapeutics reported first quarter 2026 results and highlighted progress in its oncology pipeline. The company is evaluating APR-1051 in the ACESOT-1051 Phase 1 trial, where two partial responses were observed, one of which was confirmed and remains on study. A recent $30 million private placement strengthened the balance sheet and is expected to support expanded enrollment for APR-1051.
Cash and cash equivalents rose to $46.5 million as of March 31, 2026, up from $14.6 million at December 31, 2025, which the company believes will fund operations into the first quarter of 2028. Aprea posted an operating loss of $3.4 million, down from $4.1 million a year earlier, and a net loss of $3.3 million, or ($0.22) per share, versus $3.9 million, or ($0.66) per share, in the prior-year quarter.
Aprea Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on director elections, auditor ratification, a potential reverse stock split and executive pay matters. The June 16, 2026 meeting will be held online for holders of record as of April 21, 2026.
Stockholders will vote on electing three Class I directors to 2029, ratifying EisnerAmper LLP as auditor for 2026, approving a reverse stock split at a Board-selected ratio between 1-for-3 and 1-for-8 without reducing authorized shares, and two advisory “say on pay” items. A proposal also allows adjourning the meeting to seek more proxies if needed for the reverse split.
Aprea Therapeutics, Inc. is registering 74,349,426 shares of Common Stock for resale by the selling stockholders. The registration covers (i) 37,174,713 shares issuable upon exercise of pre-funded warrants and (ii) 37,174,713 shares issuable upon exercise of common warrants issued in a March 31, 2026 private placement. We are not offering any shares for sale ourselves and will not receive proceeds from resales; we will receive cash proceeds only if outstanding warrants are exercised for cash. The exercise prices are $0.001 for the pre-funded warrants and $0.683 for the common warrants; the common warrants expire December 31, 2029, subject to certain terms. Shares outstanding were 11,982,776 as of March 31, 2026. The registration permits public or private resales by the listed selling holders, including transfers to successors, and includes beneficial ownership blockers limiting exercises to 4.99% (or, at holder election, 9.99%) ownership.
Aprea Therapeutics disclosure: reporting persons report beneficial ownership of 1,186,294 shares (9.9% of the class). The filing states the total includes 170,753 common shares issuable upon exercise of warrants and excludes 10,155,621 warrants that are not currently exercisable due to beneficial ownership limitations. The filing attributes sole voting power for 1,015,541 shares and sole dispositive power for 1,186,294 shares to the reporting persons, which are AIGH Capital Management LLC, AIGH Investment Partners LLC and Orin Hirschman.
Aprea Therapeutics, Inc. has filed a shelf registration on Form S-3 to register 74,349,426 shares of Common Stock for resale by selling stockholders. The shares represent up to 37,174,713 shares underlying pre-funded warrants and up to 37,174,713 shares underlying common warrants issued in a private placement closed March 31, 2026. The company will not receive proceeds from resales but will receive cash if warrants are exercised for cash. The registration includes customary beneficial ownership blockers (4.99% or, if elected, 9.99%).
The prospectus also summarizes clinical-stage programs: WEE1 inhibitor APR-1051 (dose escalation up to 220 mg cohort; two unconfirmed partial responses reported), ATR inhibitor ATRN-119 with an RP2D of 1,100 mg once daily, and an early-stage DYRK1 program with IND-enabling studies planned in Q4 2026. Shares outstanding were 11,982,776 as of March 31, 2026.
Aprea Therapeutics, Inc. filed a proxy statement soliciting votes for its 2026 virtual Annual Meeting to be held June 16, 2026, including election of three Class I directors and ratification of EisnerAmper LLP as auditor. The proxy also seeks approval to amend the Certificate of Incorporation to permit a reverse stock split at a ratio between one‑for‑three and one‑for‑eight, with the exact ratio and timing to be set by the Board in its sole discretion.
The record date for voting is April 21, 2026, and the filing discloses 12,382,776 shares outstanding as of April 21, 2026. The Board recommends FOR all named proposals and explains that the reverse split is intended principally to attempt to regain or maintain compliance with Nasdaq’s $1.00 minimum bid price requirement.